Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities (2011 - 2026)

Ani Pharmaceuticals has disclosed Other Non-Current Liabilities across 13 years of filings, most recently posting $8.6 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $8.6 million, up 22.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.6 million (up 22.51% YoY), and the FY2025 annual result was $12.2 million, up 110.41% from the prior year.
• Other Non-Current Liabilities came in at $8.6 million for Q1 2026 at Ani Pharmaceuticals, down from $12.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $35.1 million in Q4 2022 to a low of $4.7 million in Q2 2024.
• The 5-year median for Other Non-Current Liabilities is $11.6 million (2024), against an average of $14.6 million.
• Across the five-year window, Other Non-Current Liabilities soared 349.4% in 2022 and slumped 86.28% in 2023, its largest moves.
• Ani Pharmaceuticals' Other Non-Current Liabilities stood at $35.1 million in 2022, then plunged by 86.28% to $4.8 million in 2023, then grew by 20.21% to $5.8 million in 2024, then surged by 110.41% to $12.2 million in 2025, then retreated by 29.3% to $8.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $8.6 million (Q1 2026), $12.2 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.